Quarterly report pursuant to Section 13 or 15(d)

Investment in Macrophage Therapeutics, Inc. (Narrative) (Details)

v3.5.0.2
Investment in Macrophage Therapeutics, Inc. (Narrative) (Details) - USD ($)
 1 Months Ended
Jul. 31, 2016
May 31, 2016
Dec. 31, 2015
Sep. 30, 2016
Schedule Of Investments [Line Items]        
Current liability in form of compensation     $ 6,183,850 $ 63,763,839
Macrophage Therapeutics [Member]        
Schedule Of Investments [Line Items]        
Additional investment contribution amount   $ 200,000 200,000  
Current liability in form of compensation       $ 200,000
Percentage of paid-in-kind coupon rate on convertible preferred stock 10.00%      
Initial market capitalization $ 500,000,000      
Authorized issuance of additional convertible preferred stock   $ 200,000 $ 200,000  
Macrophage Therapeutics [Member] | Platinum [Member]        
Schedule Of Investments [Line Items]        
Authorized modification of original investments 300,000      
Macrophage Therapeutics [Member] | Dr. Goldberg [Member]        
Schedule Of Investments [Line Items]        
Authorized modification of original investments $ 200,000